Benjamin N. Nigjeh Email & Phone Number

Development of native, intact, and top/down technologies

Alameda, California, Us

-Conducted structural analysis of key oncogenic proteins to support X-ray crystallography and cryo-electron microscopy (Cryo-EM).-Collaborated with cross-functional teams to design and execute experiments aimed at elucidating the structural basis of protein function and its role in cancer development.-Applied advanced computational modeling techniques to interpret experimental data and generate structural models of protein complexes.-Prepared reports and presentations to cross-functional teams to contribute to the understanding of oncogenic mechanisms and potential therapeutic targets.

Boston, Ma, Us

-Led GLP-compliant pharmacokinetic (PK) studies to profile drug candidates in animal models, focusing on tissue and blood distribution.-Designed and executed study protocols, ensuring compliance with regulatory guidelines and quality standards.-Developed and validated analytical methods for quantifying drug concentrations in various matrices using LC-MS/MS and other analytical techniques.-Analyzed PK data and generated comprehensive reports to support drug development decision-making.-Collaborated with cross-functional teams to interpret PK results and optimize drug candidate selection and dosing strategies.-Utilized mass spectrometry (MS) techniques to characterize sodium channel proteins, focusing on identifying and quantifying post-translational modifications (PTMs) and novel binding sites.-Developed and optimized MS methods for the analysis of complex protein samples, including sample preparation, chromatographic separation, and data acquisition.-Collaborated with research teams to design experiments and interpret MS data to elucidate the structure-function relationships of sodium channel proteins.-Applied mass spectrometry (MS) techniques to characterize the cystic fibrosis transmembrane conductance regulator (CFTR) protein expressed after treatment with lipid nanoparticle (LNP)-delivered mRNA in cell culture, animal models, and human samples.-Developed and optimized MS methods for the analysis of CFTR protein, including sample preparation, chromatographic separation, and data analysis.-Collaborated with multidisciplinary teams to design experiments and interpret MS data to understand the expression, structure, and function of CFTR protein in different models.-Identified and quantified post-translational modifications (PTMs) and protein-protein interactions of CFTR to elucidate its role in cystic fibrosis pathophysiology.

La Jolla, Ca, Us

-Led activity-based ATP probe profiling of endogenous key kinases before and after non-covalent engagement with small molecules for drug potency and specificity screening.-Developed and optimized assays to assess kinase activity and small molecule engagement using activity-based probes and mass spectrometry.-Collaborated cross-functionally to design and execute experiments aimed at identifying and validating drug targets for various diseases.-Analyzed and interpreted complex data sets to assess drug potency and specificity, contributing to lead optimization and candidate selection.-Conducted drug stability and metabolite profiling from human liver microsomes, and lipid analysis from tissue samples using mass spectrometry (MS) and chromatography techniques.-Developed and validated analytical methods for the quantification of drug metabolites and lipids, ensuring data accuracy and reliability.-Collaborated with multidisciplinary teams to design and execute studies aimed at understanding drug metabolism and lipid homeostasis.

Los Angeles, Ca, Us

-Managed a state-of-the-art proteomics core facility, providing high-quality proteomics services and support to over 40 research groups across multiple institutes.-Collaborated with researchers to design and implement proteomics experiments, including sample preparation, mass spectrometry analysis, and data interpretation.-Established and maintained standard operating procedures (SOPs) for proteomics workflows, ensuring quality control and data reproducibility.-Mentored and trained staff and researchers in proteomics techniques and data analysis tools.Managed budget, equipment maintenance, and facility operations to ensure efficient and effective service delivery.

Seattle, Wa, Us

-Led the development of an extensive clinical blood assay capable of quantifying over 3500 blood proteins from less than 10 microliters of human plasma, enabling high-throughput biomarker discovery and validation studies.-Conducted global identification of circulating glycoproteins, employing mass spectrometry-based proteomics and glycoproteomics techniques to profile glycoprotein signatures associated with pancreatic cancer and other diseases.-Discovered novel circulating glycoproteins for the early diagnosis of pancreatic cancer, contributing to the development of a minimally invasive diagnostic test.-Performed statistical analysis of a biomarker panel for the highly sensitive and specific diagnosis of pancreatic cancer, validating its clinical utility and potential for early detection.-Published research findings in high-impact journals and presented at scientific conferences to advance the field of clinical proteomics and biomarker discovery for cancer diagnostics.

Buffalo, Ny, Us

-Developed a highly sensitive and accurate targeted quantification technique for the pre-clinical assessment of pharmacokinetic parameters for therapeutic proteins from tissue and blood of animal models, enabling precise measurement of drug levels and evaluation of drug efficacy.-Conducted global discovery proteomics pharmacodynamic studies after a single-dose drug administration in animal models, elucidating activated signaling pathways and supporting pharmacokinetic/pharmacodynamic (PK/PD) modeling.-Utilized stable isotope labeling by amino acids in cell culture (SILAC) experiments for protein homeostasis analysis, providing insights into drug mechanism of action and potential biomarkers.-Employed nLC-Orbitrap mass spectrometry for sequencing therapeutic proteins, ensuring accurate characterization and quality control of biopharmaceutical products.-Published research findings in peer-reviewed journals and presented at scientific conferences to advance the field of proteomics and pharmacokinetics in drug development.

Groningen, Nl

-Led LC/MS identification of oxidative drug metabolites, employing state-of-the-art mass spectrometry techniques to elucidate metabolic pathways and identify potential toxic or pharmacologically active metabolites.-Developed SRM-based quantification methods for drug metabolites, enabling precise measurement of metabolite concentrations in biological samples and supporting pharmacokinetic studies.-Designed and optimized in vitro assays for studying oxidative drug metabolism by Cytochrome P450 enzymes, providing valuable insights into drug-drug interactions and metabolic stability.-Collaborated with multidisciplinary teams to interpret data and guide drug development strategies, ensuring the safety and efficacy of pharmaceutical compounds.-Published research findings in high-impact journals and presented at scientific conferences to advance the field of drug metabolism and analytical chemistry.

Postdoc, Clinical Proteomics

Postdoc, Preclinical Proteomics

Phd, Analytical Biochemistry

Master Of Science (M.Sc.), Materials Science And Engineering: Electroanalytical Chemistry

Bachelor'S Degree (Bsc), Materials Science And Engineering: Electroanalytical Chemistry